Compass Therapeutics (CMPX) Debt to Equity (2019 - 2021)

Compass Therapeutics has disclosed Debt to Equity across 3 years of filings, most recently posting $0.16 for Q3 2021.

• Debt to Equity for Q3 2021 came in at $0.16, down 33.77% year-over-year; the trailing twelve-month figure through Sep 2021 was $0.16 (down 33.77% YoY), and the FY2020 annual result was $0.23, down 73.1% from the prior year.
• Debt to Equity came in at $0.16 for Q3 2021 at Compass Therapeutics, down from $0.22 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.87 in Q4 2019 to a low of $0.16 in Q3 2021.
• The 3-year median for Debt to Equity is $0.24 (2020), against an average of $0.33.
• Across the five-year window, Debt to Equity tumbled 73.1% in 2020 and tumbled 33.77% in 2021, its largest moves.
• Compass Therapeutics' Debt to Equity stood at $0.87 in 2019, then slumped by 73.1% to $0.23 in 2020, then slumped by 32.93% to $0.16 in 2021.
• The last three Debt to Equity figures came in at $0.16 (Q3 2021), $0.22 (Q1 2021), and $0.23 (Q4 2020), per Business Quant data.